Biden’s cancer moonshot aims to spur cutting-edge tech and simple prevention

Key Facts

• Leaders in cancer innovation said regulatory hurdles to clinical trial diversity, yawning gaps in access to preventive screenings, and inefficiencies in the market for cancer drugs still stand in the way.
• Currently, Wegrzyn said, cancer care often involves a series of surgeries because it’s so difficult to remove all the cancerous tissue and the process can damage nerves.
• PROVIDING EQUAL ACCESS TO CARE WOULD YIELD HUGE DIVIDENDS Ensuring greater access to clinical trials and improving the pipelines of new treatments to people with limited access to care will cut death rates among communities of color and rural patients who now suffer disproportionately, the experts said.
• But Tolaney said there’s still more the administration could do to reduce barriers to participation in clinical trials, such as eliminating requirements that patients go to a trial facility in person for all appointments.

Click To Read Full Article